Literature DB >> 25848016

Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.

Caleigh Mandel-Brehm1, John Salogiannis1, Sameer C Dhamne2, Alexander Rotenberg2, Michael E Greenberg3.   

Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder arising from loss-of-function mutations in the maternally inherited copy of the UBE3A gene, and is characterized by an absence of speech, excessive laughter, cognitive delay, motor deficits, and seizures. Despite the fact that the symptoms of AS occur in early childhood, behavioral characterization of AS mouse models has focused primarily on adult phenotypes. In this report we describe juvenile behaviors in AS mice that are strain-independent and clinically relevant. We find that young AS mice, compared with their wild-type littermates, produce an increased number of ultrasonic vocalizations. In addition, young AS mice have defects in motor coordination, as well as abnormal brain activity that results in an enhanced seizure-like response to an audiogenic challenge. The enhanced seizure-like activity, but not the increased ultrasonic vocalizations or motor deficits, is rescued in juvenile AS mice by genetically reducing the expression level of the activity-regulated cytoskeleton-associated protein, Arc. These findings suggest that therapeutic interventions that reduce the level of Arc expression have the potential to reverse the seizures associated with AS. In addition, the identification of aberrant behaviors in young AS mice may provide clues regarding the neural circuit defects that occur in AS and ultimately allow new approaches for treating this disorder.

Entities:  

Keywords:  ARC; Angelman syndrome; EEG; EPHEXIN5; ultrasonic vocalizations

Mesh:

Substances:

Year:  2015        PMID: 25848016      PMCID: PMC4413330          DOI: 10.1073/pnas.1504809112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome.

Authors:  R D Nicholls; J H Knoll; M G Butler; S Karam; M Lalande
Journal:  Nature       Date:  1989-11-16       Impact factor: 49.962

2.  Analysis of EEG patterns and genotypes in patients with Angelman syndrome.

Authors:  Martina Vendrame; Tobias Loddenkemper; Marcin Zarowski; Matt Gregas; Hans Shuhaiber; Dean P Sarco; Augusto Morales; Mark Nespeca; Cia Sharpe; Kevin Haas; Gregory Barnes; Daniel Glaze; Sanjeev V Kothare
Journal:  Epilepsy Behav       Date:  2012-02-16       Impact factor: 2.937

3.  Maternal behavior, pup vocalizations, and pup temperature changes following handling in mice of 2 inbred strains.

Authors:  M B Hennessy; J Li; E L Lowe; S Levine
Journal:  Dev Psychobiol       Date:  1980-11       Impact factor: 3.038

4.  Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome.

Authors:  Thorfinn T Riday; Elyse C Dankoski; Michael C Krouse; Eric W Fish; Paul L Walsh; Ji Eun Han; Clyde W Hodge; R Mark Wightman; Benjamin D Philpot; C J Malanga
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

5.  UBE3A/E6-AP mutations cause Angelman syndrome.

Authors:  T Kishino; M Lalande; J Wagstaff
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

6.  Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome.

Authors:  Michel Baudry; Eniko Kramar; Xiaobo Xu; Homera Zadran; Stephanie Moreno; Gary Lynch; Christine Gall; Xiaoning Bi
Journal:  Neurobiol Dis       Date:  2012-04-16       Impact factor: 5.996

7.  Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome.

Authors:  Kiyoshi Egawa; Kyoko Kitagawa; Koichi Inoue; Masakazu Takayama; Chitoshi Takayama; Shinji Saitoh; Tatsuya Kishino; Masatoshi Kitagawa; Atsuo Fukuda
Journal:  Sci Transl Med       Date:  2012-12-05       Impact factor: 17.956

8.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

9.  Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.

Authors:  Hsien-Sung Huang; John A Allen; Angela M Mabb; Ian F King; Jayalakshmi Miriyala; Bonnie Taylor-Blake; Noah Sciaky; J Walter Dutton; Hyeong-Min Lee; Xin Chen; Jian Jin; Arlene S Bridges; Mark J Zylka; Bryan L Roth; Benjamin D Philpot
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 10.  Understanding the pathogenesis of Angelman syndrome through animal models.

Authors:  Nihar Ranjan Jana
Journal:  Neural Plast       Date:  2012-07-08       Impact factor: 3.599

View more
  33 in total

Review 1.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

Review 2.  Angelman Syndrome.

Authors:  Seth S Margolis; Gabrielle L Sell; Mark A Zbinden; Lynne M Bird
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

3.  Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.

Authors:  Matthew C Judson; Alain C Burette; Courtney L Thaxton; Alaine L Pribisko; Mark D Shen; Ashley M Rumple; Wilmer A Del Cid; Beatriz Paniagua; Martin Styner; Richard J Weinberg; Benjamin D Philpot
Journal:  J Neurosci       Date:  2017-06-29       Impact factor: 6.167

4.  Disturbed Prefrontal Cortex Activity in the Absence of Schizophrenia-Like Behavioral Dysfunction in Arc/Arg3.1 Deficient Mice.

Authors:  Xiaoyan Gao; Jasper Grendel; Mary Muhia; Sergio Castro-Gomez; Ute Süsens; Dirk Isbrandt; Matthias Kneussel; Dietmar Kuhl; Ora Ohana
Journal:  J Neurosci       Date:  2019-09-05       Impact factor: 6.167

5.  Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.

Authors:  Michael S Sidorov; Matthew C Judson; Hyojin Kim; Marie Rougie; Alejandra I Ferrer; Viktoriya D Nikolova; Natallia V Riddick; Sheryl S Moy; Benjamin D Philpot
Journal:  J Neurosci       Date:  2018-02-05       Impact factor: 6.167

6.  Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model.

Authors:  Leeyup Chung; Alexandra L Bey; Aaron J Towers; Xinyu Cao; Il Hwan Kim; Yong-Hui Jiang
Journal:  Neurobiol Dis       Date:  2017-10-31       Impact factor: 5.996

7.  Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Authors:  Rebecca Dutta; Jacqueline N Crawley
Journal:  Neuroscience       Date:  2019-11-12       Impact factor: 3.590

8.  Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.

Authors:  Bin Gu; Kelly E Carstens; Matthew C Judson; Katherine A Dalton; Marie Rougié; Ellen P Clark; Serena M Dudek; Benjamin D Philpot
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

9.  GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility.

Authors:  Matthew C Judson; Michael L Wallace; Michael S Sidorov; Alain C Burette; Bin Gu; Geeske M van Woerden; Ian F King; Ji Eun Han; Mark J Zylka; Ype Elgersma; Richard J Weinberg; Benjamin D Philpot
Journal:  Neuron       Date:  2016-03-24       Impact factor: 17.173

10.  Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.

Authors:  Andie Dodge; Melinda M Peters; Hayden E Greene; Clifton Dietrick; Robert Botelho; Diana Chung; Jonathan Willman; Austin W Nenninger; Stephanie Ciarlone; Siddharth G Kamath; Pavel Houdek; Alena Sumová; Anne E Anderson; Scott V Dindot; Elizabeth L Berg; Henriette O'Geen; David J Segal; Jill L Silverman; Edwin J Weeber; Kevin R Nash
Journal:  Autism Res       Date:  2020-01-21       Impact factor: 5.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.